Predictive Oncology (NASDAQ: POAI) recently announced
the appointment of Pam Prior, CPA, to the company’s Board of Directors. In
addition to holding a seat on the board, Prior will also chair the company’s
audit committee. An article further discussing the company reads, “Prior, 57,
joins POAI’s Board of Directors with 35 years of experience in accounting,
mainly in management as CFO or controller. As the founder and CEO of Priorities
Group Inc., a provider of CFO services to small and mid-sized businesses, she
has served as a CFO to a number of companies, including Gentris Corp., a
private pharmacogenomics company subsequently purchased by Cancer Genetics Inc.
Most recently, Prior was CFO at Schiller Grounds Care, a privately held
lawn-and-garden equipment manufacturer. . . . Other previous CFO experience
includes working with companies in the health-industry space such as Global
Specimen Solutions, a privately held technology company for specimen and
consent management (later purchased by Covance), and multimillion-dollar
companies in other industries such as Greatwide Truckload Management, a $300
million subsidiary of a $1 billion, privately held, logistics company.”
To view the full article, visit http://ibn.fm/3EpaV
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through five
segments (domestic, international, clinical, CRO and DCHIP), which contain four
subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
Helomics applies artificial intelligence to its rich data gathered from patient
tumors to both personalize cancer therapies for patients and drive the
development of new targeted therapies in collaborations with pharmaceutical
companies. Helomics’ CLIA-certified lab provides clinical testing that assists
oncologists in individualizing patient-treatment decisions by providing an
evidence-based road map for therapy. In addition to its proprietary
precision-oncology platform, Helomics offers boutique CRO services that
leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range
of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered
proprietary bioinformatics platform (“D- CHIP”) to provide a tailored solution
to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary
is developing a new rapid approach to growing tumors in the laboratory, which
essentially “fools” cancer cells into thinking they are still growing inside a
patient. Its proprietary Oncology Discovery Technology Platform kits will
assist researchers and clinicians to identify which cancer cells bind to
specific biomarkers. Once the biomarkers are identified, they can be used in
TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help
categorize an individual patient’s heterogeneous tumor samples to enable the
development of patient-specific treatment options. Helomics and TumorGenesis
are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division
markets its patented and FDA-cleared STREAMWAY System, which automates the
collection, measurement and disposal of waste fluid, including blood,
irrigation fluid and others, within a medical facility, through both domestic
and international divisions. The company has achieved sales in five of the
seven continents through both direct sales and distributor partners. For more
information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment